|
Oct 9
|
IMab (IMAB) Moves to Buy: Rationale Behind the Upgrade
|
|
Jul 15
|
I-Mab Announces Leadership Transitions
|
|
May 2
|
Q1 2024 Summit Therapeutics Inc Earnings Call
|
|
Apr 30
|
I-MAB Filed 2023 Annual Report on Form 20-F
|
|
Apr 5
|
I-Mab to Participate at the 23rd Annual Needham Virtual Healthcare Conference
|
|
Apr 2
|
I-Mab Announces Closing of the Divestiture of Business Operations in China
|
|
Mar 18
|
I-Mab Full Year 2023 Earnings: Revenues Beat Expectations, EPS Lags
|
|
Mar 14
|
I-Mab Reports Full Year 2023 Financial Results and Business Update
|
|
Feb 7
|
UPDATE 2-Biotech firm I-Mab to divest China operations, shift focus to US
|
|
Feb 7
|
I-Mab Signs Agreement to Divest its Assets and Business Operations in China
|
|
Nov 6
|
I-Mab Announces Participation at Jefferies and Piper Conferences in November
|
|
Nov 2
|
Felzartamab Granted Breakthrough Therapy Designation by U.S. Food and Drug Administration (FDA) for Primary Membranous Nephropathy (PMN)
|